Catalyst Pharmaceuticals has successfully transitioned into a highly profitable specialty neurology player, evidenced by operating margins reaching 49.0% in 2026Q1. While the firm benefits from an asset-light model and a fortress balance sheet with $755.9M in ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 11, 2026 | $0.52-18.8% vs $0.64 | $149M-0.1% vs $150M |
Q1 2026 Feb 25, 2026 | $0.42+0.0% vs $0.42 | $153M+6.8% vs $143M |
Q4 2025 Nov 5, 2025 | $0.43-15.7% vs $0.51 | $148M+8.5% vs $137M |
Q3 2025 Aug 6, 2025 | $0.43-25.9% vs $0.58 | $147M+4.3% vs $140M |
A Deep Dive into the Small-Cap Pioneer's Latest Moves, Including a -0.42% Impact from Exiting a Major StakeCharles M. Royce, a pioneer of small-cap investing an
California State Teachers Retirement System raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 27.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,716 shares of the biopharmaceutical company's stock after purchasing an additional 30,717 shares during the quarter.
Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving Italian state lender CDP.
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst's product portfolio The transaction is being carried out with the participation of funds managed by Blackstone CDP Equity approves €1 billion investment in Angelini Pharma Italy remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.
Benchmark CPRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Catalyst Pharmaceuticals, Inc. (CPRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $31.49 | $3.85B | 18.74 | 19.78% | 36.39% | 25.49% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $62.34 | $5.17B | 8.01 | 114.51% | -3.8% | — | — | |
| $513.02 | $11.83B | -39.92 | 432.05% | -25.32% | -56.65% | — |
Catalyst Pharmaceuticals, Inc. (CPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Catalyst Pharmaceuticals, Inc. (CPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 16, 2026·SEC
Jul 8, 2026·SEC
Jun 30, 2026·SEC
Get notified when CPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Catalyst Pharmaceuticals, Inc. (CPRX) stock FAQ — growth, dividends, profitability & financials explained
Catalyst Pharmaceuticals, Inc. (CPRX) reported $597.0M in revenue for fiscal year 2025.
Catalyst Pharmaceuticals, Inc. (CPRX) grew revenue by 19.8% over the past year. This is strong growth.
Yes, Catalyst Pharmaceuticals, Inc. (CPRX) is profitable, generating $221.3M in net income for fiscal year 2025 (36.4% net margin).
Catalyst Pharmaceuticals, Inc. (CPRX) has a return on equity (ROE) of 25.5%. This is excellent, indicating efficient use of shareholder capital.
Catalyst Pharmaceuticals, Inc. (CPRX) generated $208.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
